| Clinical Trial |
Year |
ClinicalStage |
LymphNodeStage |
EvaluatedTreatment |
AxillaryRelapse |
Residual axillarydisease |
OverallSurvivall |
| NSABP 04 (12) |
1977 |
I |
cN0 |
LA |
19% |
40% |
No benefit |
| Ragaz Trial (13) |
1997 |
II, III |
N1, N2, N3 |
RTP |
22% vs 12% |
- |
0,05 |
| DBCG 82 (15) |
1997 |
II, III |
N1, N2, N3 |
RTP |
26% vs 5% |
- |
Benefit |
| Milan Trial (16) |
2003 |
I |
N0 |
LA |
0% |
4,6% |
No benefit |
| NSABP 32 (17) |
2007 |
I |
N0 |
LA |
0,2% |
9,8% |
No benefit |
| GIVOM Trial (18) |
2008 |
I |
N0 |
LA |
0,2% |
7,3% |
- |
| ACOSOG Z0011 (14) |
2010 |
I |
N1 |
LA |
1,8% vs 3,6% |
27,3% |
No benefit |
| AATRM 048/13/2000 (19) |
2013 |
IB |
N1mic |
LA |
2,5% vs 1% |
13% |
No benefit |
| IBCSG 23-01 (20) |
2013 |
IB |
N1mic |
LA |
1% vs 0,2% |
13% |
No benefit |
| AMAROS (21) |
2014 |
II |
N1 |
LA vs RTP |
0,5% vs 0,1 |
33% |
No benefit |
| MA20 (22) |
2015 |
I, II, III |
N0, N1, N2 |
LA vs RTP |
2,5% vs 0,5% |
- |
No benefit |
| EORTC 22922 (23) |
2015 |
I, II, III |
N0, N1, N2, N3 |
RTP |
1,9% vs 1,3% |
- |
No benefit |
|
